Skip to content

Author

K. Arbour

We have 2 of 130 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Sep 2026

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

BACKGROUND RAS mutations, as a group, are the most common oncogenic drivers of non-small-cell lung cancer (NSCLC), and they occur in approximately 30% of patients. Whether daraxonrasib (RMC-6236) - an oral RAS(ON) multiselective, tri-complex inhibitor of guanosine triphosphate-bound mutant and wild-type RAS protein iso...

K. Arbour, S. Punekar, Jia Luo et al. · 1 citation
Open access Sep 2026

Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity

MSK-Tox provides an empirical basis for a new precision safety paradigm for predicting who will be harmed by a therapy on the same principles that guide prediction of therapeutic benefit, and identifies two modes of germline susceptibility to treatment toxicity.

Z. Bakouny, X. Guo, F. Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.